A Study Utilizing Patient-Reported and Radiographic Outcomes and Evaluating the Safety and Efficacy of Lorecivivint (SM04690) for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis

PHASE3CompletedINTERVENTIONAL
Enrollment

513

Participants

Timeline

Start Date

May 17, 2019

Primary Completion Date

August 20, 2021

Study Completion Date

August 20, 2021

Conditions
Knee Osteoarthritis
Interventions
DRUG

Lorecivivint

Healthcare professional-administered intra-articular injection; performed on Day 1

DRUG

Placebo

Healthcare professional-administered intra-articular injection; performed on Day 1

Trial Locations (99)

10016

Research Site, New York

10021

Research Site 1, New York

Research Site 2, New York

10530

Research Site, Hartsdale

11021

Research Site, Great Neck

14221

Research Site, Williamsville

14609

Research Site, Rochester

16635

Research Site, Duncansville

20902

Research Site, Wheaton

22911

Research Site, Charlottesville

23219

Research Site, Richmond

27103

Research Site, Winston-Salem

28144

Research Site, Salisbury

28209

Research Site, Charlotte

28451

Research Site, Leland

29464

Research Site, Mt. Pleasant

29607

Research Site, Greenville

29651

Research Site, Greer

29707

Research Site, Fort Mill

30060

Research Site, Marietta

30189

Research Site, Woodstock

30265

Research Site, Newnan

30281

Research Site, Stockbridge

32127

Research Site, Port Orange

32765

Research Site, Oviedo

32789

Research Site #1, Winter Park

Research Site #2, Winter Park

32806

Research Site, Orlando

33014

Research Site, Miami Lakes

33016

Research Site, Hialeah

33134

Research Site, Coral Gables

33143

Research Site, Miami

33351

Research Site, Sunrise

33409

Research Site, West Palm Beach

33761

Research Site, Clearwater

33880

Research Site, Winter Haven

35205

Research Site, Birmingham

35215

Research Site, Birmingham

35216

Research Site, Birmingham

43235

Research Site, Columbus

45219

Research Site, Cincinnati

45224

Research Site, Cincinnati

45242

Research Site, Cincinnati

46011

Research Site, Anderson

46383

Research Site, Valparaiso

47714

Research Site, Evansville

48085

Research Site, Troy

48706

Research Site, Bay City

57702

Research Site, Rapid City

58104

Research Site, Fargo

60031

Research Site, Gurnee

60523

Research Site, Oak Brook

61114

Research Site, Rockford

61704

Research Site, Bloomington

63042

Research Site, Hazelwood

63141

Research Site, St Louis

66160

Research Site, Kansas City

67205

Research Site, Wichita

68114

Research Site, Omaha

68128

Research Site, La Vista

68516

Research Site, Lincoln

70124

Research Site, New Orleans

71203

Research Site, Monroe

72205

Research Site, Little Rock

73103

Research Site, Oklahoma City

73112

Research Site, Oklahoma City

75007

Research Site, Carrollton

75075

Research Site, Plano

75231

Research Site, Dallas

76021

Research Site, Bedford

77029

Research Site, Houston

77055

Research Site, Houston

78215

Research Site, San Antonio

78229

Research Site, San Antonio

78258

Research Site, San Antonio

78539

Research Site, Edinburg

78745

Research Site, Austin

80209

Research Site, Denver

80301

Research Site, Boulder

80918

Research Site, Colorado Springs

83642

Research Site, Meridian

83713

Research Site, Boise

84020

Research Site, Draper

84107

Research Site, Salt Lake City

84123

Research Site, Murray

85037

Research Site, Phoenix

85381

Research Site, Peoria

85712

Research Site, Tucson

87108

Research Site, Albuquerque

91767

Research Site, Pomona

91978

Research Site, Spring Valley

92078

Research Site, San Marcos

92103

Research Site, San Diego

92683

Research Site, Westminster

92805

Research Site, Anaheim

92840

Research Site, Garden Grove

92860

Research Site, Norco

06708

Research Site, Waterbury

02111

Research Site, Boston

Sponsors
All Listed Sponsors
lead

Biosplice Therapeutics, Inc.

INDUSTRY